docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-5-89-94docru-251Research ArticleГИНЕКОЛОГИЯGYNECOLOGYВедение пациенток с генитальным эндометриозом: новые стратегииManagement of Patients with Genital Endometriosis: New Strategieshttps://orcid.org/0000-0002-6537-3436ЕрмоловаН. В.ErmolovaN. V.

Наталья Викторовна Ермолова,  д. м. н., доцент, начальник отдела, профессор

акушерско-гинекологический отдел; кафедра акушерства и гинекологии № 2

344022; Нахичеванский пер., д. 29; Ростов-на-Дону

344022; 29 Nahichevansky Ave.; Rostov-on-Don

rniiap.ermolova@gmail.comhttps://orcid.org/0000-0002-2348-8809ПетровЮ. А.PetrovYu. A.

Юрий Алексеевич Петров, д. м. н., профессор, заведующий кафедрой

кафедра акушерства и гинекологии № 2

344022; Нахичеванский пер., д. 29; Ростов-на-Дону

344022; 29 Nahichevansky Ave.; Rostov-on-Don

mr.doctorpetrov@mail.ruhttps://orcid.org/0000-0001-8047-7148ЛевковичМ. А.LevkovichM. A.

Марина Аркадьевна Левкович, д. м. н., доцент, ведущий научный сотрудник

отдел аллергии и аутоиммунных заболеваний

344022; Нахичеванский пер., д. 29; Ростов-на-Дону

344022; 29 Nahichevansky Ave.; Rostov-on-Don

xlma@mail.ruСавченкоА. В.SavchenkoA. V.

Анастасия Викторовна Савченко, врач — акушер-гинеколог

344068; ул. Бодрая, д. 88/35; Ростов-на-Дону

344068; 88/35 Bodraya Str.; Rostov-on-Don

savnas2014@yandex.ruСлесареваК. В.SlesarevaK. V.

Кристина Витальевна Слесарева, к. м. н., врач — акушер-гинеколог

Научно-исследовательский институт акушерства и педиатрии; отделение гинекологии

344022; Нахичеванский пер., д. 29; Ростов-на-Дону

344022; 29 Nahichevansky Ave.; Rostov-on-Don

slesareva.rniiap@yandex.ruФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияRostov State Medical UniversityRussian FederationГБУ РО «Городская больница скорой медицинской помощи в г. Ростове-на-Дону»РоссияCity Emergency Hospital in Rostov-on-DonRussian Federation202319022025225ГИНЕКОЛОГИЯ8994Copyright © Ермолова Н.В., Петров Ю.А., Левкович М.А., Савченко А.В., Слесарева К.В., 20252025Ермолова Н.В., Петров Ю.А., Левкович М.А., Савченко А.В., Слесарева К.В.Ermolova N.V., Petrov Y.A., Levkovich M.A., Savchenko A.V., Slesareva K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/251   Цель обзора

   Цель обзора: провести анализ современных подходов к диагностике и лечению генитального эндометриоза.

   Основные положения

   Основные положения. Эндометриоз — это одно из самых распространенных гинекологических заболеваний, поражающее прежде всего женщин репродуктивного возраста, основные проявления которого — хроническая тазовая боль и бесплодие. Постоянная снижающая качество жизни тазовая боль приводит к тому, что пациентки находятся в состоянии длительного стресса, и у них возникают расстройства поведения. Согласно последним мировым рекомендациям, медикаментозное лечение — первая линия терапии эндометриоза, если беременность не является приоритетной задачей на данном этапе. Существует множество визуализационных методов диагностики этого заболевания, однако до сих пор продолжается поиск неинвазивных маркеров эндометриоза, позволяющих достоверно подтвердить диагноз.

   Заключение

   Заключение. Междисциплинарный подход и выбор адекватного лечения эндометриоза на каждом этапе жизни женщины могут ограничить ненужные хирургические вмешательства и лучше удовлетворять потребности пациенток.

   Aim

   Aim: To analyze modern approaches to the diagnosis and treatment of genital endometriosis.

   Key points

   Key points. Endometriosis is one of the most common gynecological diseases, affecting mainly women of reproductive age, the main manifestations of which are chronic pelvic pain and infertility. Constant pelvic pain, which reduces the quality of life, leads to the fact that patients are in a state of prolonged stress, and they have behavioral disorders. According to the latest world recommendations, drug treatment is the first line of therapy for endometriosis, if pregnancy is not a priority at this stage. There are many imaging methods for diagnosing this disease, but the search for non-invasive markers of endometriosis that can reliably confirm the diagnosis is still ongoing.

   Conclusion

   Conclusion. An interdisciplinary approach and the choice of adequate treatment for endometriosis at each stage of a woman's life can limit unnecessary surgery and better meet the needs of patients.

эндометриозаденомиозхроническая тазовая больпрогестиныдиеногестмаркеры эндометриозаendometriosisadenomyosischronic pelvic painprogestinsdienogestendometriosis markersReferencesZondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N. Engl. J. Med. 2020;382(13):1244–56. DOI: 10.1056/NEJMra1810764Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N. Engl. J. Med. 2020;382(13):1244–56. DOI: 10.1056/NEJMra1810764Hill C.J., Fakhreldin M., Maclean A., Dobson L. et al. Endometriosis and fallopian tubes: theories of origin and clinical implications. J. Clin. Med. 2020;9(6):1905. DOI: 10.3390/jcm9061905Hill C.J., Fakhreldin M., Maclean A., Dobson L. et al. Endometriosis and fallopian tubes: theories of origin and clinical implications. J. Clin. Med. 2020;9(6):1905. DOI: 10.3390/jcm9061905Parazzini F., Esposito G., Tozzi L., Noli S. et al. Epidemiology of endometriosis and its comorbidities. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017;209:3–7. DOI: 10.1016/j.ejogrb.2016.04.021Parazzini F., Esposito G., Tozzi L., Noli S. et al. Epidemiology of endometriosis and its comorbidities. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017;209:3–7. DOI: 10.1016/j.ejogrb.2016.04.021Gambadauro P., Carli V., Hadlaczky G. Depressive symptoms among women with endometriosis : a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2019;220(3):230–41. DOI: 10.1016/j.ajog.2018.11.123Gambadauro P., Carli V., Hadlaczky G. Depressive symptoms among women with endometriosis : a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2019;220(3):230–41. DOI: 10.1016/j.ajog.2018.11.123As-Sanie S., Black R., Giudice L.C., Gray Valbrun T. et al. Assessing research gaps and unmet needs in endometriosis. Am. J. Obstet. Gynecol. 2019;221(2):86–94. DOI: 10.1016/j.ajog.2019.02.033As-Sanie S., Black R., Giudice L.C., Gray Valbrun T. et al. Assessing research gaps and unmet needs in endometriosis. Am. J. Obstet. Gynecol. 2019;221(2):86–94. DOI: 10.1016/j.ajog.2019.02.033Škegro B., Bjedov S., Mikuš M., Mustač F. et al. Endometriosis, pain and mental health. Psychiatr. Danub. 2021;33(suppl.4):632–6.Škegro B., Bjedov S., Mikuš M., Mustač F. et al. Endometriosis, pain and mental health. Psychiatr. Danub. 2021;33(suppl.4):632–6.Casalechi M., Vieira-Lopes M., Quessada M.P., Arão T.C. et al. Endometriosis and related pelvic pain: association with stress, anxiety and depressive symptoms. Minerva Obstet Gynecol. 2021;73(3):283–9. DOI: 10.23736/S2724-606X.21.04704-3Casalechi M., Vieira-Lopes M., Quessada M.P., Arão T.C. et al. Endometriosis and related pelvic pain: association with stress, anxiety and depressive symptoms. Minerva Obstet Gynecol. 2021;73(3):283–9. DOI: 10.23736/S2724-606X.21.04704-3Walker A.K., Kavelaars A., Heijnen C.J., Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol. Rev. 2013;66(1):80–101. DOI: 10.1124/pr.113.008144Walker A.K., Kavelaars A., Heijnen C.J., Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol. Rev. 2013;66(1):80–101. DOI: 10.1124/pr.113.008144Harsanyi S., Kupcova I., Danisovic L., Klein M. Selected biomarkers of depression: what are the effects of cytokines and inflammation? Int. J. Mol. Sci. 2022;24(1):578. DOI: 10.3390/ijms24010578Harsanyi S., Kupcova I., Danisovic L., Klein M. Selected biomarkers of depression: what are the effects of cytokines and inflammation? Int. J. Mol. Sci. 2022;24(1):578. DOI: 10.3390/ijms24010578Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009;71(2):171–86. DOI: 10.1097/PSY.0b013e3181907c1bHowren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009;71(2):171–86. DOI: 10.1097/PSY.0b013e3181907c1bNabi M.Y., Nauhria S., Reel M., Londono S. et al. Endometriosis and irritable bowel syndrome: a systematic review and meta-analyses. Front. Med. (Lausanne). 2022;9:914356. DOI: 10.3389/fmed.2022.914356Nabi M.Y., Nauhria S., Reel M., Londono S. et al. Endometriosis and irritable bowel syndrome: a systematic review and meta-analyses. Front. Med. (Lausanne). 2022;9:914356. DOI: 10.3389/fmed.2022.914356Schomacker M.L., Hansen K.E., Ramlau-Hansen C.H., Forman A. Is endometriosis associated with irritable bowel syndrome? A cross-sectional study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018;231:65–9. DOI: 10.1016/j.ejogrb.2018.10.023Schomacker M.L., Hansen K.E., Ramlau-Hansen C.H., Forman A. Is endometriosis associated with irritable bowel syndrome? A cross-sectional study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018;231:65–9. DOI: 10.1016/j.ejogrb.2018.10.023Baker J.M., Al-Nakkash L., Herbst-Kralovetz M.M. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45–53. DOI: 10.1016/j.maturitas.2017.06.025Baker J.M., Al-Nakkash L., Herbst-Kralovetz M.M. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45–53. DOI: 10.1016/j.maturitas.2017.06.025Rowlands I.J., Hockey R., Abbott J.A., Montgomery G.W. et al. Body mass index and the diagnosis of endometriosis: findings from a national data linkage cohort study. Obes. Res. Clin. Pract. 2022;16(3):235–41. DOI: 10.1016/j.orcp.2022.04.002Rowlands I.J., Hockey R., Abbott J.A., Montgomery G.W. et al. Body mass index and the diagnosis of endometriosis: findings from a national data linkage cohort study. Obes. Res. Clin. Pract. 2022;16(3):235–41. DOI: 10.1016/j.orcp.2022.04.002Vercellini P., Eskenazi B., Consonni D., Somigliana E. et al. Oral contraceptives and risk of endometriosis : a systematic review and meta-analysis. Hum. Reprod. Update. 2011;17(2):159–70. DOI: 10.1093/humupd/dmq042Vercellini P., Eskenazi B., Consonni D., Somigliana E. et al. Oral contraceptives and risk of endometriosis : a systematic review and meta-analysis. Hum. Reprod. Update. 2011;17(2):159–70. DOI: 10.1093/humupd/dmq042Chapron C., Souza C., Borghese B., Lafay-Pillet M.C. et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum. Reprod. 2011;26(8):2028–35. DOI: 10.1093/humrep/der156Chapron C., Souza C., Borghese B., Lafay-Pillet M.C. et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum. Reprod. 2011;26(8):2028–35. DOI: 10.1093/humrep/der156Moura A.P.C., Ribeiro H.S.A.A., Bernardo W.M., Simões R. et al. Accuracy of transvaginal sonography versus magnetic resonance imaging in the diagnosis of rectosigmoid endometriosis : systematic review and meta-analysis [published correction appears in PLoS One. 2019;14(8):e0221499]. PLoS One. 2019;14(4):e0214842. DOI: 10.1371/journal.pone.0214842Moura A.P.C., Ribeiro H.S.A.A., Bernardo W.M., Simões R. et al. Accuracy of transvaginal sonography versus magnetic resonance imaging in the diagnosis of rectosigmoid endometriosis : systematic review and meta-analysis [published correction appears in PLoS One. 2019;14(8):e0221499]. PLoS One. 2019;14(4):e0214842. DOI: 10.1371/journal.pone.0214842Chowdary P., Stone K., Ma T., Readman E. et al. Multicentre retrospective study to assess diagnostic accuracy of ultrasound for superficial endometriosis — are we any closer? Aust. N. Z. J. Obstet. Gynaecol. 2019;59(2):279–84. DOI: 10.1111/ajo.12911Chowdary P., Stone K., Ma T., Readman E. et al. Multicentre retrospective study to assess diagnostic accuracy of ultrasound for superficial endometriosis — are we any closer? Aust. N. Z. J. Obstet. Gynaecol. 2019;59(2):279–84. DOI: 10.1111/ajo.12911Guo C., Zhang C. Platelet-to-lymphocyte ratio and CA125 level as a combined biomarker for diagnosing endometriosis and predicting pelvic adhesion severity. Front. Oncol. 2022;12:896152. DOI: 10.3389/fonc.2022.896152Guo C., Zhang C. Platelet-to-lymphocyte ratio and CA125 level as a combined biomarker for diagnosing endometriosis and predicting pelvic adhesion severity. Front. Oncol. 2022;12:896152. DOI: 10.3389/fonc.2022.896152Xue Y.H., You L.T., Ting H.F., Chen Y.W. et al. Increased risk of rheumatoid arthritis among patients with endometriosis: a nationwide population-based cohort study. Rheumatology (Oxford). 2021;60(7):3326–33. DOI: 10.1093/rheumatology/keaa784Xue Y.H., You L.T., Ting H.F., Chen Y.W. et al. Increased risk of rheumatoid arthritis among patients with endometriosis: a nationwide population-based cohort study. Rheumatology (Oxford). 2021;60(7):3326–33. DOI: 10.1093/rheumatology/keaa784Kusunoki M., Fujiwara Y., Komohara Y., Imamura Y. et al. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. Med. Mol. Morphol. 2021;54(2):122–32. DOI: 10.1007/s00795-020-00272-4Kusunoki M., Fujiwara Y., Komohara Y., Imamura Y. et al. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. Med. Mol. Morphol. 2021;54(2):122–32. DOI: 10.1007/s00795-020-00272-4Chapron C., Marcellin L., Borghese B., Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat. Rev. Endocrinol. 2019;15(11):666–82. DOI: 10.1038/s41574-019-0245-zChapron C., Marcellin L., Borghese B., Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat. Rev. Endocrinol. 2019;15(11):666–82. DOI: 10.1038/s41574-019-0245-zKitajima M., Khan K.N., Harada A., Taniguchi K. et al. Association between ovarian endometrioma and ovarian reserve. Front. Biosci. (Elite Ed). 2018;10(1):92–102. DOI: 10.2741/e810Kitajima M., Khan K.N., Harada A., Taniguchi K. et al. Association between ovarian endometrioma and ovarian reserve. Front. Biosci. (Elite Ed). 2018;10(1):92–102. DOI: 10.2741/e810Muzii L., Galati G., Di Tucci C., Di Feliciantonio M. et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol. Endocrinol. 2020;36(1):81–3. DOI: 10.1080/09513590.2019.1640199Muzii L., Galati G., Di Tucci C., Di Feliciantonio M. et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol. Endocrinol. 2020;36(1):81–3. DOI: 10.1080/09513590.2019.1640199Králíčková M., Laganà A.S., Ghezzi F., Vetvicka V. Endometriosis and risk of ovarian cancer: what do we know? Arch. Gynecol. Obstet. 2020;301(1):1–10. DOI: 10.1007/s00404-019-05358-8Králíčková M., Laganà A.S., Ghezzi F., Vetvicka V. Endometriosis and risk of ovarian cancer: what do we know? Arch. Gynecol. Obstet. 2020;301(1):1–10. DOI: 10.1007/s00404-019-05358-8Pejovic T., Thisted S., White M., Nezhat F.R. Endometriosis and endometriosis-associated ovarian cancer (EAOC). Adv. Exp. Med. Biol. 2020;1242:73–87. DOI: 10.1007/978-3-030-38474-6_5Pejovic T., Thisted S., White M., Nezhat F.R. Endometriosis and endometriosis-associated ovarian cancer (EAOC). Adv. Exp. Med. Biol. 2020;1242:73–87. DOI: 10.1007/978-3-030-38474-6_5Khan K.N., Fujishita A., Koshiba A., Kuroboshi H. et al. Biological differences between intrinsic and extrinsic adenomyosis with coexisting deep infiltrating endometriosis. Reprod. Biomed. Online. 2019;39(2):343–53. DOI: 10.1016/j.rbmo.2019.03.210Khan K.N., Fujishita A., Koshiba A., Kuroboshi H. et al. Biological differences between intrinsic and extrinsic adenomyosis with coexisting deep infiltrating endometriosis. Reprod. Biomed. Online. 2019;39(2):343–53. DOI: 10.1016/j.rbmo.2019.03.210Chapron C., Vannuccini S., Santulli P., Abrão M.S. et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum. Reprod. Update. 2020;26(3):392–411. DOI: 10.1093/humupd/dmz049Chapron C., Vannuccini S., Santulli P., Abrão M.S. et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum. Reprod. Update. 2020;26(3):392–411. DOI: 10.1093/humupd/dmz049Tellum T., Nygaard S., Lieng M. Noninvasive diagnosis of adenomyosis : a structured review and meta-analysis of diagnostic accuracy in imaging. J. Minim. Invasive Gynecol. 2020;27(2):408–18.e3. DOI: 10.1016/j.jmig.2019.11.001Tellum T., Nygaard S., Lieng M. Noninvasive diagnosis of adenomyosis : a structured review and meta-analysis of diagnostic accuracy in imaging. J. Minim. Invasive Gynecol. 2020;27(2):408–18.e3. DOI: 10.1016/j.jmig.2019.11.001Saraswat L., Ayansina D., Cooper K.G., Bhattacharya S. et al. Impact of endometriosis on risk of further gynaecological surgery and cancer: a national cohort study. BJOG. 2018;125(1):64–72. DOI: 10.1111/1471-0528.14793Saraswat L., Ayansina D., Cooper K.G., Bhattacharya S. et al. Impact of endometriosis on risk of further gynaecological surgery and cancer: a national cohort study. BJOG. 2018;125(1):64–72. DOI: 10.1111/1471-0528.14793Edi R., Cheng T. Endometriosis: evaluation and treatment. Am. Fam. Physician. 2022;106(4):397–404.Edi R., Cheng T. Endometriosis: evaluation and treatment. Am. Fam. Physician. 2022;106(4):397–404.Vercellini P., Buggio L., Frattaruolo M.P., Borghi A. et al. Medical treatment of endometriosis-related pain. Best Pract. Res. Clin. Obstet. Gynaecol. 2018;51:68–91. DOI: 10.1016/j.bpobgyn.2018.01.015Vercellini P., Buggio L., Frattaruolo M.P., Borghi A. et al. Medical treatment of endometriosis-related pain. Best Pract. Res. Clin. Obstet. Gynaecol. 2018;51:68–91. DOI: 10.1016/j.bpobgyn.2018.01.015Piacenti I., Viscardi M.F., Masciullo L., Sangiuliano C. et al. Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice? Gynecol. Endocrinol. 2021;37(5):471–5. DOI: 10.1080/09513590.2021.1892632Piacenti I., Viscardi M.F., Masciullo L., Sangiuliano C. et al. Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice? Gynecol. Endocrinol. 2021;37(5):471–5. DOI: 10.1080/09513590.2021.1892632Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017;107(3):533–6. DOI: 10.1016/j.fertnstert.2017.01.003Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017;107(3):533–6. DOI: 10.1016/j.fertnstert.2017.01.003Murji A., Biberoğlu K., Leng J., Mueller M.D. et al. Use of dienogest in endometriosis : a narrative literature review and expert commentary. Curr. Med. Res. Opin. 2020;36(5):895–907. DOI: 10.1080/03007995.2020.1744120Murji A., Biberoğlu K., Leng J., Mueller M.D. et al. Use of dienogest in endometriosis : a narrative literature review and expert commentary. Curr. Med. Res. Opin. 2020;36(5):895–907. DOI: 10.1080/03007995.2020.1744120Hughes G.C., Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat. Rev. Rheumatol. 2014;10(12):740–51. DOI: 10.1038/nrrheum.2014.144Hughes G.C., Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat. Rev. Rheumatol. 2014;10(12):740–51. DOI: 10.1038/nrrheum.2014.144Collins M.K., McCutcheon C.R., Petroff M.G. Impact of estrogen and progesterone on immune cells and host-pathogen interactions in the lower female reproductive tract. J. Immunol. 2022;209(8):1437–49. DOI: 10.4049/jimmunol.2200454Collins M.K., McCutcheon C.R., Petroff M.G. Impact of estrogen and progesterone on immune cells and host-pathogen interactions in the lower female reproductive tract. J. Immunol. 2022;209(8):1437–49. DOI: 10.4049/jimmunol.2200454Moulton V.R. Sex hormones in acquired immunity and autoimmune disease. Front. Immunol. 2018;9:2279. DOI: 10.3389/fimmu.2018.02279Moulton V.R. Sex hormones in acquired immunity and autoimmune disease. Front. Immunol. 2018;9:2279. DOI: 10.3389/fimmu.2018.02279Liu Y., Wang J., Zhang X. An update on the multifaceted role of NF-kappa B in endometriosis. Int. J. Biol. Sci. 2022;18(11):4400–13. DOI: 10.7150/ijbs.72707Liu Y., Wang J., Zhang X. An update on the multifaceted role of NF-kappa B in endometriosis. Int. J. Biol. Sci. 2022;18(11):4400–13. DOI: 10.7150/ijbs.72707Mita S., Shimizu Y., Notsu T., Imada K. et al. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil. Steril. 2011;96(6):1485–9.e4. DOI: 10.1016/j.fertnstert.2011.09.040Mita S., Shimizu Y., Notsu T., Imada K. et al. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil. Steril. 2011;96(6):1485–9.e4. DOI: 10.1016/j.fertnstert.2011.09.040Arosh J.A., Sivakumar K.K., Lee J., Banu S.K. Effects of selective inhibition of prostaglandin E2 receptors EP2 and EP4 on the miRNA profile in endometriosis. Mol. Cell Endocrinol. 2022;558:111728. DOI: 10.1016/j.mce.2022.111728Arosh J.A., Sivakumar K.K., Lee J., Banu S.K. Effects of selective inhibition of prostaglandin E2 receptors EP2 and EP4 on the miRNA profile in endometriosis. Mol. Cell Endocrinol. 2022;558:111728. DOI: 10.1016/j.mce.2022.111728Koshiba A., Mori T., Okimura H., Akiyama K. et al. Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries. J. Obstet. Gynaecol. Res. 2018;44(10):1970–6. DOI: 10.1111/jog.13725Koshiba A., Mori T., Okimura H., Akiyama K. et al. Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries. J. Obstet. Gynaecol. Res. 2018;44(10):1970–6. DOI: 10.1111/jog.13725Lee J.H., Song J.Y., Yi K.W., Lee S.R. et al. Effectiveness of dienogest for treatment of recurrent endometriosis: multicenter data. Reprod. Sci. 2018;25(10):1515–22. DOI: 10.1177/1933719118779733Lee J.H., Song J.Y., Yi K.W., Lee S.R. et al. Effectiveness of dienogest for treatment of recurrent endometriosis: multicenter data. Reprod. Sci. 2018;25(10):1515–22. DOI: 10.1177/1933719118779733Vignali M., Belloni G.M., Pietropaolo G., Barbasetti Di Prun A. et al. Effect of dienogest therapy on the size of the endometrioma. Gynecol. Endocrinol. 2020;36(8):723–7. DOI: 10.1080/09513590.2020.1725965Vignali M., Belloni G.M., Pietropaolo G., Barbasetti Di Prun A. et al. Effect of dienogest therapy on the size of the endometrioma. Gynecol. Endocrinol. 2020;36(8):723–7. DOI: 10.1080/09513590.2020.1725965Del Pup L., Berretta M. As dienogest effectively suppress could it also reduce endometriosis associated ovarian cancers? A further motivation for long-term medical treatment. World Cancer Res. J. 2015;2(2):e526.Del Pup L., Berretta M. As dienogest effectively suppress could it also reduce endometriosis associated ovarian cancers? A further motivation for long-term medical treatment. World Cancer Res. J. 2015;2(2):e526.Vannuccini S., Luisi S., Tosti C., Sorbi F. et al. Role of medical therapy in the management of uterine adenomyosis. Fertil. Steril. 2018;109(3):398–405. DOI: 10.1016/j.fertnstert.2018.01.013Vannuccini S., Luisi S., Tosti C., Sorbi F. et al. Role of medical therapy in the management of uterine adenomyosis. Fertil. Steril. 2018;109(3):398–405. DOI: 10.1016/j.fertnstert.2018.01.013Ota I., Taniguchi F., Ota Y., Nagata H. et al. A controlled clinical trial comparing potentprogestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis. Reprod. Med. Biol. 2021;20(4):427–34. DOI: 10.1002/rmb2.12408Ota I., Taniguchi F., Ota Y., Nagata H. et al. A controlled clinical trial comparing potentprogestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis. Reprod. Med. Biol. 2021;20(4):427–34. DOI: 10.1002/rmb2.12408Yang S., Liu Y., Wen J., Sun Y. et al. Clinical efficacy of dienogest versus levonorgestrel-releasing intrauterine system for adenomyosis. Evid. Based Complement Alternat. Med. 2022;2022:1995472. DOI: 10.1155/2022/1995472Yang S., Liu Y., Wen J., Sun Y. et al. Clinical efficacy of dienogest versus levonorgestrel-releasing intrauterine system for adenomyosis. Evid. Based Complement Alternat. Med. 2022;2022:1995472. DOI: 10.1155/2022/1995472Green I.C., Burnett T., Famuyide A. Persistent pelvic pain in patients with endometriosis. Clin. Obstet. Gynecol. 2022;65(4):775–85. DOI: 10.1097/GRF.0000000000000712Green I.C., Burnett T., Famuyide A. Persistent pelvic pain in patients with endometriosis. Clin. Obstet. Gynecol. 2022;65(4):775–85. DOI: 10.1097/GRF.0000000000000712

The authors declare that there are no conflicts of interest present.